Israel - English - Ministry of Health

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - tablets - desogestrel 150 mcg; ethinylestradiol 30 mcg - desogestrel and estrogen - desogestrel and estrogen - oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - water for injections, quantity: 0.85 ml - diluent, not applicable - excipient ingredients: - this product approved for registration as an amendment to a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the therapeutic goods act 1989. indications are held in artg paper records. (old code)

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - bezlotoxumab - concentrate for solution for infusion - bezlotoxumab 25 mg / 1 ml - bezlotoxumab - zinplava is indicated for the prevention of recurrence of clostridium difficile infection (cdi) in adults who are receiving antibacterial drug treatment of cdi and are at high risk for recurrence of cdi

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - ceftolozane as sulfate; tazobactam as sodium - powder for concentrate for solution for infusion - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor - zerbaxa is indicated for the treatment of the following infections in adults:-complicated intra abdominal infections;-acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture-complicated urinary tract infections.-hospital-acquired pneumonia (hap), including ventilator-associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - pembrolizumab - powder for solution for infusion - pembrolizumab 50 mg/vial - pembrolizumab - - melanoma:keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma.- non-small cell lung cancer:• keytruda, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (nsclc) negative for egfr or alk genomic tumor aberrations.• keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous nsclc. • keytruda, as a single agent, is indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors express pd-l1 [tumor proportion score (tps) ≥50%)] as determined by a validated test. patients with egfr or alk genomic tumor aberrations should have disease progression on or after platinum-containing chemotherapy and an approved therapy for these aberrations prior to receiving keytruda.• keytruda, as a single agent, is indic

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 350 [iu] in 0.42 ml - follistim® aq cartridge (follitropin beta) injection, is indicated: in women for: prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation. - primary ovarian failure should be excluded. - the possibility of pregnancy should be excluded. - tubal patency should be demonstrated. - the fertility status of the male partner should be evaluated. prior to initiation of treatment with follistim aq cartridge: - women should have a complete gynecologic and endocrinologic evaluation and diagnosis of cause of infertility. - the possibility of pregnancy should be excluded. - the fertility status of the male partner should be evaluated. in men for: prior to initiation of treatment with follistim aq cartridge: - men should have a complete medical and endocrinologic evaluation. - hypogonadotropic hypogonadism should be confirmed and primary testicular failure should be excluded. - serum testosterone levels should be normalized with human chorionic